Transforming Lives Through Innovative Medicines

Insmed is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for patients with serious and rare diseases. Located in Bridgewater, New Jersey, Insmed is driven by a mission to provide hope for underserved patient populations. The company leverages its industry-leading R&D capabilities to create innovative medicines that address unmet medical needs. Insmed's lead product, ARIKAYCE, is the first and only therapy approved in the US for refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. Beyond ARIKAYCE, Insmed is advancing a robust pipeline of earlier-stage candidates like brensocatib and TPIP, which have potential in diseases such as bronchiectasis and sarcoidosis. With a patient-focused culture and commitment to high ethical standards, Insmed aims to bring meaningful improvements to patients' lives while operating responsibly and transparently.

Insmed is publicly traded on the Nasdaq stock exchange under the ticker symbol INSM. The company partners with healthcare professionals, patient advocacy groups, and charitable organizations to maximize its impact. Insmed has a global footprint, with operations in the US, Europe, and Japan.